Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Paul Prescott Just Put MAIA Biotechnology, Inc.
(NYSE American: MAIA) At The Top Of The Watchlist
This Morning—Wednesday, July 8, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Check Out MAIA While It’s Still Early… July 8, 2026 Dear Reader, This morning, MAIA Biotechnology, Inc. (NYSE American: MAIA) announced positive initial efficacy data from Part C of its Phase 2 THIO-101 expansion trial that is worth understanding in full context. The trial reported a 90.5% interim disease control rate across 19 out of 21 efficacy-evaluable patients treated with ateganosine followed by cemiplimab — results that are consistent with the 88% disease control rate previously reported in Parts A and B, and notably achieved in a patient group that was more heavily pre-treated, with all participants having already received docetaxel on top of demonstrating resistance to prior immunotherapy and chemotherapy. For reference, current chemotherapy in this setting delivers an approximate 25 to 35% disease control rate. When data holds up across a harder population, that tends to be worth paying attention to — and that is precisely why MAIA is at the top of the Street Ideas watchlist this morning. On June 25, 2026, MAIA announced the completion of international enrollment in Part C of its Phase 2 THIO-101 expansion trial for third-line non-small cell lung cancer—a patient population with no effective standard of care and approximately 50,000 new cases per year in the U.S. alone. Domestic enrollment is now underway at three U.S. clinical sites, including Georgia's only NCI-designated Comprehensive Cancer Center at Emory University. MAIA has been sitting near the $1.50 range recently, while Noble Capital Markets continues to carry a $14 target. 
What separates MAIA from the broader small-cap biotech field is the combination of a clinically active Phase 3 pivotal trial, Phase 2 data that meaningfully outperforms the current standard of care, and a regulatory portfolio that reflects FDA recognition of both the science and the unmet medical need behind the program. The Phase 3 THIO-104 trial — the pivotal study positioned to support full commercial approval — began treating patients in December 2025. Within six months, 34 clinical sites had opened across six countries and 29 patients had begun treatment. Noble projects the trial reaching 100 enrolled patients by year-end 2026, creating the potential for an interim overall survival analysis in 2027. Using a Bayesian statistical framework applied to Phase 2 survival data, the firm calculates a 96% probability of success at the interim analysis and 99% at the final analysis. Full pipeline details are available in MAIA’s corporate presentation here. The Phase 2 THIO-101 trial produced a median overall survival of 17.8 months in third-line NSCLC patients — a population where standard chemotherapy typically delivers approximately 5.8 months. The combination also achieved an 88% disease control rate and a 38% overall response rate, both substantially above historical benchmarks for this indication. These are the numbers that informed the Phase 3 design and underpin Noble’s probability-of-success model. According to Benzinga, several members of MAIA's leadership team recently made purchases, complementing a series of recent clinical and regulatory developments. 
Getting To Know MAIA Biotechnology, Inc. (NYSE American: MAIA)
MAIA Biotechnology is a clinical-stage biopharmaceutical company based in Chicago, Illinois. The company is developing ateganosine, also known as THIO, an experimental cancer therapy designed to target telomeres, which play an important role in the way cancer cells continue growing. MAIA’s lead program is focused on third-line non-small cell lung cancer, or NSCLC, a difficult-to-treat patient population that has already received prior immunotherapy and chemotherapy. According to the company, there is currently no FDA-approved standard of care for this group. The company’s active clinical work includes the Phase 2 THIO-101 expansion trial and the Phase 3 THIO-104 pivotal trial. MAIA has also secured clinical supply agreements with BeOne Medicines and Roche for planned or future studies in additional cancer indications. MAIA’s regulatory portfolio includes 3 FDA Orphan Designations, 1 Rare Pediatric Disease Designation, and 1 Fast Track Designation for third-line NSCLC. Its intellectual property portfolio includes 10 issued patents validated across 19 European countries, 36 pending applications, and exclusivity extending into the early 2040s. The leadership team also brings deep oncology and finance experience, led by CEO Vlad Vitoc, MD, MBA, CSO Sergei Gryaznov, PhD, and Head of Finance Jeffrey Himmelreich, MBA. How MAIA's Approach Differs From Standard Checkpoint
Inhibitor Therapy
Checkpoint inhibitors have become one of the largest areas in oncology, led by widely used therapies such as Keytruda, Opdivo, and Libtayo. NSCLC remains one of the most important treatment areas in this category. However, the third-line NSCLC setting remains a difficult and underserved segment. These are patients who have already received prior immunotherapy and chemotherapy, and according to MAIA, there is currently no FDA-approved standard of care for this group. That is where MAIA’s approach is focused. Its lead therapy, ateganosine, is designed to be used before a checkpoint inhibitor with the goal of making cancer cells more responsive to immune-based treatment. MAIA is also exploring this approach beyond NSCLC, including planned studies in colorectal cancer, hepatocellular carcinoma, and small cell lung cancer. The company has clinical supply agreements with Regeneron, BeOne Medicines, and Roche, each connected to checkpoint inhibitor combination programs. For readers, the key point is straightforward: MAIA is working in a large oncology category, but its lead focus is a specific patient group where treatment options remain limited. Latest MAIA Highlights
June 25, 2026 International THIO-101 Part C Enrollment Complete: MAIA completed international patient enrollment in the Phase 2 THIO-101 expansion trial Part C, with domestic enrollment now active at three U.S. sites. See full story here. June 22, 2026 Noble Capital Markets Reiterates Outperform, $14.00: Analyst Robert LeBoyer published an updated report citing Phase 3 enrollment momentum, new U.S. expansion sites, and a Bayesian probability model placing interim Phase 3 success at 96%. See full story here. June 18, 2026 Emory Winship Cancer Institute Activated: MAIA opened enrollment at Georgia's only NCI-designated Comprehensive Cancer Center, adding significant institutional credibility to the U.S. THIO-101 expansion footprint. See full story here. June 10, 2026 Second U.S. THIO-101 Expansion Site Opened: MAIA activated its second domestic clinical site for the THIO-101 Phase 2 international expansion trial, noting that expansion data may support an accelerated FDA approval filing. See full story here. June 4, 2026 Phase 3 Reports Strong Enrollment and Dosing Momentum: MAIA reported that the THIO-104 Phase 3 pivotal trial had opened 34 sites across six countries and treated 29 patients within six months of first dosing. See full story here. June 3, 2026 FDA Clears IND for U.S. Phase 2 THIO-101 Enrollment: MAIA received FDA clearance to open U.S. sites in the THIO-101 expansion trial. The updated IND incorporated the latest efficacy data and a refined patient selection strategy. See full story here. June 2, 2026 CEO and Director Make Open-Market Share Purchases: MAIA's CEO and a board director purchased shares in the open market, signaling internal conviction at current levels. See full story here. June 1, 2026 Phase 3 Poster Presented at 2026 ASCO Annual Meeting: MAIA presented a Trial in Progress poster for the THIO-104 Phase 3 pivotal trial at the 2026 American Society of Clinical Oncology annual meeting. See full story here. This Is Why MAIA Just Moved To The Top Of Our Watchlist On Wednesday Morning, July 8, 2026… 1. Recent FDA Progress: MAIA recently completed international enrollment in Part C of its Phase 2 trial while U.S. enrollment continues following FDA clearance earlier this month.
2. Phase 3 Active: MAIA is already treating patients in its pivotal Phase 3 THIO-104 study, with 34 clinical sites open across six countries within the first six months. 3. Strong Clinical Data: MAIA reported a median overall survival of 17.8 months in its Phase 2 THIO-101 trial, compared with approximately 5.8 months typically seen with standard chemotherapy in this patient population. 4. Regulatory Recognition: MAIA has received multiple FDA designations, including 3 Orphan Designations, 1 Rare Pediatric Disease Designation, and 1 Fast Track Designation for its lead program. 5. Expanding Pipeline: MAIA is advancing programs beyond NSCLC through clinical supply agreements with Regeneron, BeOne Medicines, and Roche while planning additional studies across multiple cancer indications. 6. Leadership Purchases: According to Benzinga, several members of MAIA's leadership team have recently made open-market share purchases alongside a series of clinical and regulatory updates. 7. Analyst Coverage: MAIA continues to receive coverage from Noble Capital Markets, which reiterated a bullish rating and $14 target in a June 22, 2026 report. Check Out MAIA While It’s Still Early…
Some companies keep moving onto our screen because the updates simply don't stop. That's exactly what happened at Street Ideas with MAIA. Recent clinical progress, FDA activity, expanding collaborations, analyst coverage, and leadership share purchases reported by Benzinga all contributed to making it one of today's featured companies. MAIA has our full focus this morning. Take a look while it’s still early, and keep an eye out for my next update Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter |
